In 2023, 3.8 million people were being treated for diabetes (Santé publique France), with type 2 diabetes accounting for the vast majority of cases (92 %). In line with the increase in obesity and the ageing population, this form of diabetes has been growing rapidly for several years. Furthermore, according to the French health insurance system, the number of people with diabetes receiving treatment represents a total expenditure of €10.2 billion, or 5.3 % of total compulsory health insurance expenditure.
Preventing the causes and factors contributing to the development of this disease is a major challenge in limiting these expenses. The Court of Accounts, which has already examined obesity prevention and health prevention policy, is therefore taking another look at this disease. More specifically, it is focusing on prevention and early treatment, in light of recent recommendations from the Haute Autorité de Santé (HAS, the French National Authority for Health).
